Thea Pharma Inc. Highlights Commitment to Improving Eye Care at the American Academy of Optometry Annual Meeting

Educational symposium, presentation, and booth presence at Academy 2023 will showcase innovation in managing primary open-angle glaucoma (POAG) and ocular hypertension (OHT)

WALTHAM, Massachusetts – **October 3, 2023** – Thea Pharma Inc. ("Thea"), the U.S. subsidiary of Europe's leading independent ophthalmic-focused pharmaceutical company, Laboratories Théa, dedicated to the research, development, and commercialization of ophthalmic products, will highlight its commitment to improving eye care at the American Academy of Optometry (AAOPT) Annual Meeting, taking place in New Orleans October 11-14, 2023.

Thea's dynamic program at the AAOPT annual meeting showcases the company's leadership in eye health. Activities include an educational symposium to equip optometrists with evidence-based approaches to managing primary open-angle glaucoma (POAG) and ocular hypertension (OHT) and a presentation on IYUZEH™ (latanoprost ophthalmic solution) 0.005% as part of the 2023 American Academy of Optometry Innovations in Vision and Eye Care press program.

"POAG and OHT can significantly impact a person's quality of life, making everyday tasks more challenging for millions of people. These conditions often require lifelong treatment but, until recently, clinicians had only limited treatment options available," said Susan Benton, President of Thea Pharma, Inc. "The breadth of our presence at the AAOPT annual meeting underscores our commitment to partnering with the eye care community to improve patient outcomes."

Educational Symposium
"Beyond the Surface: Managing POAG and OHT with Evidence-Based Approaches"
October 11, 2023, 6:00pm – 9:00pm, Hilton Riverside
This AAOPT-approved educational program for U.S. optometrists will be conducted through a series of 15-20 minute live, case-based discussions by leading optometrists Jade Coats, OD; Mike Cymbor, OD, FAAO; Damon Dierker, OD, FAAO; Mitch Ibach, OD, FAAO; Danica Marrelli, OD, FAAO; and Paula Newsome, OD, MS, FAAO, FAARM, CHC. The format will encourage activate participation, allowing optometrists to ask questions, share insights, and present challenging cases for group analysis. U.S. optometrists may register at bit.ly/BeyondtheSurfaceAAOPT.

AAOPT Innovations in Vision and Eye Care Presentation
IYUZEH Presentation by Michael Chaglasian, OD
October 11, 2023, 8:00am, AAOPT and Livestream
Dr. Michael Chaglasian, Chief of Staff at the Illinois Eye Institute and Associate Professor at the Illinois College of Optometry will deliver a presentation on IYUZEH at the 2023 American Academy of Optometry Innovations in Vision and Eye Care (formerly Press Conference). IYUZEH (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) in the U.S., where latanoprost is the most

prescribed prostaglandin F2α analogue (PGA). This presentation will focus on IYUZEH's role as a treatment option for patients with POAG and OHT.

Meet Thea

Booths #1245 and #1342

Attendees will be able to connect with Thea team, speak with clinicians, and learn about the company's latest innovations in eye care during the annual meeting exhibition. Meet the Thea Commercial team at booth #1245 and learn about IYUZEH, iVIZIA™, and the company's portfolio of products designed to meet the various needs of eye care professionals and their patients. Meet the Medical team at booth #1342 and learn how Thea is working with clinicians to improve eye health.

For more information, please visit https://theapharmainc.com/.

About IYUZEH™

IYUZEH™ (latanoprost ophthalmic solution) 0.005%, an opalescent, white to slightly yellow ophthalmic solution, is a topical formulation of latanoprost that is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). IYUZEH™ does not contain a preservative – it is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA), in the United States. The recommended dosage of IYUZEH™ is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal. Reduction of the IOP starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours. IOP reduction is present for at least 24 hours.

In the two clinical trials conducted with IYUZEH™ (latanoprost ophthalmic solution) 0.005%, the most frequently reported ocular adverse reactions were conjunctival hyperemia (34%) and eye irritation (19%) compared to XALATAN®, the preserved 0.005% latanoprost reference product which reported conjunctival hyperemia (37%) and eye irritation (31%).

Healthcare providers, patients, and caregivers can learn more about IYUZEH at iyuzeh.com.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to latanoprost or any other ingredients in this product.

WARNINGS AND PRECAUTIONS

Pigmentation: Topical latanoprost ophthalmic products, including IYUZEH™ have been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is administered.

The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of latanoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known.

Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with IYUZEH™ can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Eyelash Changes: Latanoprost ophthalmic products, including IYUZEH™ may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation: IYUZEH™ should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation because inflammation may be exacerbated.

Macular Edema: Macular edema, including cystoid macular edema, has been reported during treatment with latanoprost ophthalmic products, including IYUZEH™. IYUZEH™ should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Herpetic Keratitis: Reactivation of herpes simplex keratitis has been reported during treatment with latanoprost. IYUZEH™ should be used with caution in patients with a history of herpetic keratitis. IYUZEH™ should be avoided in cases of active herpes simplex keratitis because inflammation may be exacerbated.

Contact Lens Use: Contact lenses should be removed prior to the administration of IYUZEH™ and may be reinserted 15 minutes after administration.

ADVERSE REACTIONS

The following adverse reactions have been reported with the use of topical latanoprost products: iris pigmentation changes, eyelid skin darkening, eyelash changes (increased length, thickness, pigmentation, and number of lashes), intraocular inflammation (iritis/uveitis), and macular edema, including cystoid macular edema.

DRUG INTERACTIONS

The combined use of two or more prostaglandins, or prostaglandin analogs including IYUZEH™ is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.

For more information about IYUZEH™, please visit https://iyuzeh.com.

For Full Prescribing Information, please visit https://iyuzeh.com/wp-content/uploads/2022/12/IYUZEH-Full-Prescribing-Information.pdf

About Théa

Laboratoires Théa is an independent pharmaceutical company specialized in the research, development, and commercialization of eye-care products. Based in Clermont-Ferrand, France, it has thirty-five affiliates & offices in Europe, North and South America, North Africa, and the Middle East. Today, its network includes more than 1,600 employees, and its products are available in 75 countries around the world. In 2021, Théa had global revenues of approximately $773 million. The independent and family-owned and run group, founded from a Research and Development start-up by Henri Chibret, has been chaired since 2008 by Jean-Frédéric Chibret, his nephew.

To learn more about Laboratoires Théa Group, visit https://www.laboratoires-thea.com/en/Group.

About Thea Pharma Inc.

Thea Pharma Inc., is the United States subsidiary of Théa. Its product offering is comprised of a portfolio of seven leading eye-care products that are regulated or approved by the U.S. Food and Drug Administration (FDA), including Zioptan®, AcellFX™, Cosopt®, Cosopt® PF, Azasite®, Akten®, and Betimol®, iVIZIA™ dry-eye drops and eyelid hygiene products, and now IYUZEH™. By focusing our passion and expertise within the U.S. market, Thea Pharma's goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open.

To learn more about Thea Pharma, Inc., visit https://theapharmainc.com.

Thea Pharma Inc. – U.S. Media Inquiries Please Contact:
Kristin Villiotte
SHIFT Communications
TheaPharma@shiftcomm.com

###

PRC-IYZ-1664-v2 09.2023